Key result
An alkaline diet combined with EGFR-TKI therapy in patients with EGFR mutation-positive NSCLC was associated with a median progression-free survival of 19.5 months and increased urine pH (P<0.05).
Why the study?
Does an alkaline diet improve survival outcomes in advanced NSCLC patients with EGFR mutations treated with EGFR-TKI?
Observational (n=11)
Does an alkaline diet improve survival outcomes in advanced NSCLC patients with EGFR mutations treated with EGFR-TKI?
An alkaline diet may enhance the efficacy of EGFR-TKI treatment in patients with EGFR-mutated NSCLC, potentially allowing for reduced TKI dosages.
Alkaline diet should not alter EGFR-TKI management in NSCLC; leaves open whether it enhances outcomes in prospective trials.
BACKGROUND: The acidic tumor microenvironment is associated with progression of cancers. The purpose of this study was to investigate the association between an alkaline diet and the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Eleven advanced or recurrent NSCLC patients with EGFR mutations treated with EGFR-TKI after being instructed to follow an alkaline diet were retrospectively evaluated. RESULTS: The median progression-free survival (PFS) and overall survival (OS) were 19.5 (range=3.1-33.8) and 28.5 (range=15.4-46.6) months. The average dosage of EGFR-TKI was 56±22% of the standard dosage. Urine pH was significantly increased after the alkaline diet (6.00±0.38 vs. 6.95±0.55; p<0.05). CONCLUSION: An alkaline diet may enhance the effect of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
No takes yet. Share an insight, caveat, or question.
Hamaguchi et al. (2017) conducted an observational in Advanced or recurrent non-small cell lung cancer (NSCLC) with EGFR mutations (n=11). Alkaline diet was evaluated on Progression-free survival (PFS) and overall survival (OS). An alkaline diet combined with EGFR-TKI therapy in patients with EGFR mutation-positive NSCLC was associated with a median progression-free survival of 19.5 months and increased urine pH (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: